BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25184174)

  • 21. The use of generic medications for hepatitis C.
    Freeman JA; Hill A
    Liver Int; 2016 Jul; 36(7):929-32. PubMed ID: 27306303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The new hepatitis C virus bottleneck: Can delaying therapy be justified?
    Simon TG; Chung RT
    Hepatology; 2015 Sep; 62(3):666-7. PubMed ID: 26058922
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
    Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial: Towards the eradication of hepatitis C virus.
    Marcellin P; Asselah T
    Liver Int; 2012 Feb; 32 Suppl 1():1. PubMed ID: 22212564
    [No Abstract]   [Full Text] [Related]  

  • 25. Newest Treatments for Hepatitis C: How Can We Manage Sustainability?
    Messori A
    Clin Infect Dis; 2015 Dec; 61(12):1891-2. PubMed ID: 26261204
    [No Abstract]   [Full Text] [Related]  

  • 26. The end of hepatitis C.
    Sussman NL; Remien CH; Kanwal F
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):533-6. PubMed ID: 24480676
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
    Koff RS
    J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
    [No Abstract]   [Full Text] [Related]  

  • 28. Hepatitis C Virus Treatment and Injection Drug Users: It Is Time to Separate Fact From Fiction.
    McCance-Katz EF; Valdiserri RO
    Ann Intern Med; 2015 Aug; 163(3):224-5. PubMed ID: 26120801
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cost-effectiveness of chronic hepatitis C treatment in Spain].
    Haj-Ali Saflo O; Hernández Guijo JM
    Gastroenterol Hepatol; 2009; 32(7):472-82. PubMed ID: 19615787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to Messori.
    Rein DB
    Clin Infect Dis; 2015 Dec; 61(12):1892-3. PubMed ID: 26261202
    [No Abstract]   [Full Text] [Related]  

  • 31. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
    Gellad ZF; Reed SD; Muir AJ
    Antivir Ther; 2012; 17(6 Pt B):1189-99. PubMed ID: 23186646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of generics to treat chronic hepatitis C: not quite ready for the big stage.
    Sarpel D; Dieterich D
    Liver Int; 2016 Jul; 36(7):933-5. PubMed ID: 27306304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What does it mean to put new hepatitis C drugs on a list of essential medicines?
    Urrutia J; Porteny T; Daniels N
    BMJ; 2016 Apr; 353():i2035. PubMed ID: 27106956
    [No Abstract]   [Full Text] [Related]  

  • 34. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL.
    Saag MS
    Clin Infect Dis; 2015 Jul; 61(2):169-70. PubMed ID: 25778748
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].
    Yoshida H; Tateishi R; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):511-4. PubMed ID: 15359852
    [No Abstract]   [Full Text] [Related]  

  • 36. Does patient cost sharing for HCV drugs make sense?
    Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
    [No Abstract]   [Full Text] [Related]  

  • 37. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

  • 38. Universal Medicine Access through Lump-Sum Remuneration - Australia's Approach to Hepatitis C.
    Moon S; Erickson E
    N Engl J Med; 2019 Feb; 380(7):607-610. PubMed ID: 30763190
    [No Abstract]   [Full Text] [Related]  

  • 39. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012.
    Kieran J; Bennett K; Coghlan M; Bergin C; Barry M
    Ir Med J; 2015 Jun; 108(6):166-9. PubMed ID: 26182797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.